DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease

• Forschungsstelle: INNOSUISSE
• Projektnummer: 18929.1 PFLS-LS
• Projekttitel Englisch: DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease

Kurzbeschreibung (Deutsch)

DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease

Kurzbeschreibung (Englisch)

DUAL CYTOKINE-ANTIBODY FUSIONS: next-generation antibody products for a selective modulation of the activity of the immune system at the site of disease

Abstract (Deutsch)

The use of recombinant antibodies as delivery vehicles promises to greatly enhance the therapeutic index of pro-inflammatory and anti-inflammatory cytokines. However, current generation immunocytokines do not elicit cures in vivo whereas combination immunocytokine therapies can. This project aims to develop 'second generation' immunocytokines to capitalize on this observation by combining synergistic cytokine pairs into a single therapeutic molecule

Abstract (Englisch)